NRSN

Neurosense Therapeutics Ltd

Add to Watchlist

Advanced Chart

1.080

-0.04(-3.571%)1D

Line

Candle

YTD

High

1.1383

Open

1.130

VWAP

1.09

Vol

140.06K

Mkt Cap

27.05M

Low

1.070

Amount

152.44K

EV/EBITDA(TTM)

Total Shares

18.04M

27.38M

EV/OCF(TTM)

P/S(TTM)

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

2 Analyst Rating

Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.080

Low

9.00

Averages

9.00

High

9.00

Current: 1.080

Low

9.00

Averages

9.00

High

9.00

Noble Capital

Robert LeBoyer

initiated

2025-10-14

Reason

Noble Capital

Robert LeBoyer

Price Target

2025-10-14

initiated

Reason

Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense with an Outperform rating and $9 price target. Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer's disease showed "promising data."

D. Boral Capital

Jason Kolbert

Buy

initiated

$14

2025-05-12

Reason

D. Boral Capital

Jason Kolbert

Price Target

$14

2025-05-12

initiated

Buy

Reason

Maxim Group

Naz Rahman

Strong Buy

Hold

Downgrades

n/a

2024-12-16

Reason

Maxim Group

Naz Rahman

Price Target

n/a

2024-12-16

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -3.65, compared to its 5-year average forward P/E of -2.04. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.04

Current PE

-3.65

Overvalued PE

-1.06

Undervalued PE

-3.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.22

Current PS

1.12

Overvalued PS

40.28

Undervalued PS

-23.84